What hematocrit measures
Hematocrit is the proportion of your blood volume occupied by red cells, reported as a percentage. Haemoglobin — the oxygen-carrying protein inside those cells — is measured on the same complete blood count and generally moves with it. Both are routine, cheap and reported on nearly every panel.
They matter on testosterone therapy because testosterone stimulates red cell production. When that stimulation pushes red cell mass above the normal range the result is called erythrocytosis (older reports say secondary polycythaemia). The FDA-approved Depo-Testosterone label instructs that "haemoglobin and hematocrit levels (to detect polycythaemia) should be checked periodically in patients receiving long-term androgen administration."
Why testosterone raises it
The review literature describes several contributing mechanisms rather than one: a shift in the erythropoietin set-point, suppression of hepcidin with greater iron availability for erythropoiesis, and direct stimulation of the bone marrow. Ohlander and colleagues' 2018 review of erythrocytosis following testosterone therapy notes that the effect is formulation-dependent, with "short-acting injectable formulations having the highest associated incidence" — consistent with higher peak exposure driving the response. The same review is careful to note that evidence linking therapy-induced erythrocytosis to vascular events remains limited.
Practical translation: a rising hematocrit is common enough to be expected, more likely on injectable esters, and a reason for monitoring rather than alarm. Injection frequency is one of the variables that shapes peak exposure — see the injection frequency guide.
The thresholds clinicians work from
These figures come from guidelines written for prescribers. They are included here so you recognise them when they appear in your notes — not as numbers to act on yourself.
- The Endocrine Society guideline treats an already-elevated hematocrit as a reason not to start therapy, describes reassessing it 3–6 months after starting and annually thereafter, and describes withholding testosterone when hematocrit exceeds 54% until it normalises, then resuming at a reduced dose. Therapeutic phlebotomy is discussed as a management option.
- The AUA guidance directs clinicians to measure haemoglobin and hematocrit before therapy and to inform patients of the increased risk of polycythaemia.
- The Depo-Testosterone label requires periodic checks during long-term use, without naming a numeric cut-off.
Note what none of these say: they do not tell a patient to stop therapy, donate blood or change a dose on their own reading of a number. Every one of those actions is a clinical decision, and an elevated hematocrit can also prompt a search for other causes such as sleep apnoea or smoking.
Blood donation is not therapeutic phlebotomy
These two get conflated constantly, and they are different things.
| Voluntary blood donation | Therapeutic phlebotomy | |
|---|---|---|
| Purpose | Supplying the blood system for other patients. | Treating a diagnosed condition in you. |
| Who decides | You, subject to the collection centre's donor-eligibility rules. | A clinician, as a prescribed procedure. |
| Eligibility | You must meet every donor requirement, including haemoglobin limits and interval rules — and answer the health questionnaire honestly. | Ordered for a documented indication; may be performed where donation would not be permitted. |
| Frequency | Regulated. Whole blood collection is limited to no more than once in 8 weeks (56 days) under 21 CFR 630.15; double red cell apheresis carries a longer deferral, commonly 16 weeks at US centres. | Set by the treating clinician for the indication. |
Some men on testosterone therapy donate blood, and some are advised to have therapeutic phlebotomy. Which — if either — applies to you is a question for your clinician, not a conclusion to draw from a lab report. Repeated red cell removal also depletes iron, which is why ferritin often ends up on the panel alongside hematocrit.
How TRT AI handles hematocrit
The blood donation and hematocrit planner and the app share the same logic, and it is worth being explicit about what that logic is:
- A 42–52% band. The app's reference band for hematocrit, used to show where a value sits. It is a display band, not a clinical threshold, and it is not the 54% figure guidelines discuss.
- A nudge from 51%. One cycle of buffer before the top of the band, so a rising trend surfaces before it becomes a surprise.
- An ordinary least-squares projection across your own recorded draws — a straight line through your history, deliberately simple, and only as good as the number of draws behind it.
- 56-day interval arithmetic for whole-blood spacing, so a planned donation date is not guesswork.
All of that is scheduling and visualisation. None of it is a recommendation to donate, to stop therapy or to change a dose.
Common questions
Is a hematocrit of 52% high?
It depends on your laboratory's reference interval, your baseline, your altitude and your clinical picture — and interpretation is your clinician's job. What you can do is make the number comparable: same lab, same timing, and a note of anything that shifts plasma volume, such as dehydration before the draw.
Should I donate blood to lower my hematocrit?
That is a clinical question, and this page will not answer it for you. Donation is governed by donor-eligibility rules and exists to supply other patients; managing an elevated hematocrit is a medical matter your prescriber should direct — potentially via therapeutic phlebotomy rather than donation.
How often can you give whole blood?
Under 21 CFR 630.15, a whole blood collection may not occur more than once in 8 weeks — 56 days. Double red cell apheresis carries a longer deferral, commonly 16 weeks at US centres. Individual collection centres may apply stricter rules.